RediNews
ETFs Holding ZYNE »    ZYNE Historical Stock Prices »
ZYNE News Video: Fri, Dec 9, 2016, 10:35 AM — Friday 12/9 Insider Buying Report: MDCO, ZYNE


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Zynerba Pharmaceuticals is a clinical stage pharmaceutical company focused on developing and commercializing transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients. Co. is evaluating two patent protected product candidates, ZYN002 and ZYN001, in four neuropsychiatric indications. Co. is developing ZYN002 for the treatment of Fragile X Syndrome, Developmental and Epileptic Encephalopathies, adult refractory focal epilepsy, and other indications. In addition, Co. is developing ZYN001 for the treatment of Tourette Syndrome and other indications. Self directed investors in Zynerba Pharmaceuticals Inc will be interested in keeping up with all Zynerba Pharmaceuticals Inc news they can find, both ZYNE news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ZYNE. At RediNews, we simplify this task by presenting both ZYNE news releases originating from Zynerba Pharmaceuticals Inc itself, and ZYNE news from a variety of media outlets. Visitors can browse this news online and through our ZYNE RSS news feed.

ZYNE News

ZYNE News — Articles, Videos, & Press Releases

First Week of July 19th Options Trading For Zynerba Pharmaceuticals (ZYNE)
Tuesday, May 21, 2019, 11:04 AM — Stock Options Channel
Interesting ZYNE Put And Call Options For June 21st
Monday, April 29, 2019, 11:07 AM — Stock Options Channel
Will Zynerba Pharmaceuticals Continue to Surge Higher?
Monday, April 15, 2019, 3:55 AM — Zacks
Analysts See 10% Upside For The Holdings of SPTM
Monday, March 4, 2019, 7:40 AM — ETF Channel
Implied SPTM Analyst Target Price: $38
Monday, January 21, 2019, 8:39 AM — ETF Channel
The Implied Analyst 12-Month Target For SPTM
Thursday, December 20, 2018, 7:58 AM — ETF Channel
Analysts See 23% Gains Ahead For SPSM
Wednesday, November 14, 2018, 8:24 AM — ETF Channel
First Week of December 21st Options Trading For Zynerba Pharmaceuticals (ZYNE)
Tuesday, October 30, 2018, 10:47 AM — Stock Options Channel
SPTM's Holdings Could Mean 10% Gain Potential
Thursday, October 4, 2018, 8:21 AM — ETF Channel
Interesting ZYNE Put And Call Options For May 2019
Friday, September 28, 2018, 10:39 AM — Stock Options Channel
How The Parts Add Up: SPSM Targets $36
Tuesday, August 7, 2018, 8:45 AM — ETF Channel
Notable Monday Option Activity: ZYNE, CSL, LUV
Monday, June 11, 2018, 3:18 PM — Stock Options Channel
Noteworthy Wednesday Option Activity: GRUB, ZYNE, DLTR
Wednesday, May 30, 2018, 3:17 PM — Stock Options Channel
ZYNE is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

BPMC News
TDOC News
PRAH News
GBT News
DERM News
MCRB News
AQXP News
EDG News
CFN News
DGX News

If you use web portal software to control your web site content, chances are your portal software already makes it easy for you to integrate RSS feeds from third party sources, like RediNews. Using RSS — short for Really Simple Syndication — makes content syndication a snap, so even if you have never worked with a stock data feed before, you should still have no problem working with the content delivery mechanism made possible by RSS. These RediNews RSS feeds are found throughout our website wherever news is found, whether by sector or custom content by symbol, by clicking the RSS icon for any news page (which will look like this): .

ZYNE News | www.RediNews.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.